Matas A J, Simmons R L, Kjellstrand C M, Buselmeier T J, Najarian J S
Lancet. 1975 Apr 19;1(7912):883-6. doi: 10.1016/s0140-6736(75)91684-0.
The incidence of cancer in 646 dialysis/transplant patients before uraemia developed, during the period of progressive uraemia, and post-transplantation was compared. 10 tumours (3 breast, 2 kidney, 1 leukaemia, 1 lung, 1 insulinoma, 1 thyroid, 1 cervix in situ) developed in 9 patients during the period of progressive uraemia, a significant increase over the expected number in the age-matched general population. 6 of these patients have received transplants and have no evidence of recurrent disease 6 months to 4 years post-transplantation. 11 de-novo tumours have developed in 530 transplant recipients (4 cervix in situ, 2 skin, 2 reticulum-cell sarcoma, 1 lip, 1 dysgerminoma, 1 colon)--a significant increase over the age-matched general population. The cancers in the uraemic patients are relatively common types of mesenchymal tumours while the cancers in the transplant recipients are epithelial and lymphoproliferative. This difference may reflect the presence of the graft in the transplant patient or may be due to different patterns of immunosuppression in these two populations.
对646例透析/移植患者在尿毒症发生前、进行性尿毒症期间及移植后的癌症发病率进行了比较。在进行性尿毒症期间,9例患者发生了10例肿瘤(3例乳腺癌、2例肾癌、1例白血病、1例肺癌、1例胰岛素瘤、1例甲状腺癌、1例原位宫颈癌),显著高于年龄匹配的普通人群的预期数量。其中6例患者接受了移植,移植后6个月至4年无疾病复发迹象。530例移植受者发生了11例新发肿瘤(4例原位宫颈癌、2例皮肤癌、2例网状细胞肉瘤、1例唇癌、1例无性细胞瘤、1例结肠癌),显著高于年龄匹配的普通人群。尿毒症患者的癌症多为相对常见的间充质肿瘤类型,而移植受者的癌症多为上皮性和淋巴增殖性肿瘤。这种差异可能反映了移植患者体内移植物的存在,也可能是由于这两个人群不同的免疫抑制模式所致。